Transformative or overhyped? The impact of weight-loss drugs on European food demand

Key numbers: GLP-1 market was ~$70bn in 2025 and ING estimates ~20% growth to $100bn by end-2027; current usage ~12% of US adults vs ~2% of EU+UK adults (~9–10m users). Near-term impact on European food demand is limited (EU+UK calorie demand down ~0.25% today), though users cut intake ~15–20% and 50% discontinue within a year, while a transformative scenario could cut total calorie intake 2.5–3.5% by 2030. Implication: minimal disruption to food & beverage volumes in 2026–27 but material category risk if adoption and reimbursement expand; recommended corporate responses include product reformulation/portion control, targeted marketing, and geographic reallocation to lower-use markets.

Analysis

Pharma winners capture more than drug revenues — they reshape demand elasticities across food categories and create new margin pools via higher-margin adjunct services (weight-management clinics, telehealth subscriptions). Patent cliffs and faster generic competition will compress headline prices but expand addressable populations unevenly by country, shifting where food demand erosion occurs and over what timeline.

Food companies with scale, brand equity and rapid NPD cycles (ability to premiumise, downsize portions, or reformulate to high-protein/fibre formats) will recapture much of lost volume through higher ASPs and SKU rationalisation; commodity-focused ingredient suppliers (sugar, high-fructose corn syrup, bulk dairy fats) face structural volume risk and fixed-cost exposure. Retailers and co-packers will see SKU churn and lower throughput per SKU, pressuring unit economics for high-fixed-cost packaging lines and short-run SKUs.

Key near-term catalysts that could re-rate sectors are regulatory reimbursement expansions, published long-term weight-maintenance data, and faster-than-expected oral/generic rollouts in EM markets; countervailing risks include high discontinuation and behavioural relapse that restore volumes and a policy pivot toward food-system interventions (taxes/subsidies) that change demand composition. Monitor granular KPIs (country-level reimbursed patient counts, category household penetration post-prescription, ingredient order books) for conviction shifts rather than headline adoption rates.

From an allocation standpoint, treat this as an asymmetric, multi-year thematic rebalancing: overweight pharma innovators with durable pipelines and disciplined capital returns, selectively long consumer staples with clear premiumisation playbooks, and hedge commodity-linked exposure via suppliers/packaging names that lack agility.

Key Decisions for Investors

• Long NVO (12–24 months): buy a 12–18 month call spread to capture continued GLP-1 adoption and pipeline optionality while capping premium (entry: buy 1x ITM call / sell 1x further OTM call). Rationale: secular demand + high reinvestment optionality; risk: accelerated generic entry and pricing pressure. Target ~2–3x asymmetric upside vs limited premium outlay; unwind on clear EU/EM generic launches or adverse long-term efficacy data.
• Pair trade (6–18 months): long PEP / short HSY (equal notional). Rationale: PepsiCo's broad portfolio, scale and beverage/snack mix supports premiumisation and margin retention; Hershey's concentrated confectionery exposure is more sensitive to secular volume declines. Hedge ratio ~1:1 dollar exposure; target 15–25% relative outperformance, stop-loss at 10% drawdown per leg.
• Hedge consumer staples downside (9–12 months): buy MDLZ 6–12 month OTM put spread (cheap tail protection) sized to cover 30–50% of portfolio food exposure. Rationale: protects against an accelerated transformative scenario or rapid reimbursement expansion in Europe's largest markets. Exit/roll if GLP-1 coverage expansion stalls for 2 successive quarters.
• Tactical monitoring/alpha (continuous): use ING macro/regulatory research to trigger reweights — overweight EM-listed food names that show delayed GLP-1 penetration but strong GDP growth when patented GLP-1s remain unaffordable. Reallocate if ING flags rapid reimbursement or generic production in key EM countries.